Bioventus said it tapped former Medtronic (NYSE:MDT) and Immucor (NSDQ:BLUD) chief Bill Hawkins to be its new chairman, replacing Dan LeMaitre.
Hawkins, who’s slated to appear at the upcoming DeviceTalks event in Raleigh, N.C., had the corner office at Medtronic from 2007 until 2011, when he took the helm at Immucor, where is he lead director.
Direct Flow CEO LeMaitre elected to step down, Bioventus said.
“I want to thank Dan Lemaitre for his vision, energy, sage counsel and leadership of our board of managers since Bioventus became a standalone company in 2012. His contributions to our early successes were numerous,” CEO Tony Bihl said in prepared remarks. “As we move into 2016, we are excited to have Bill Hawkins join us to lead our board as chairman. As former CEO of one of the most successful global medical device companies, Bill brings very strong experience in orthobiologics, including BMP, and we look forward to working with him and our Board to continue to grow Bioventus in this space.”
Medtronic India veep Shah retires
Dr. Milind Shah, vice president of Medtronic India, retires down effective today after a 12-year run at the company, which is conducting a search for his replacement.
Read more
LivaNova shuffles neuromod leadership
LivaNova said it named neuromodulation sales VP Jason Richey as president of the division, replacing Rohan Hoare effective immediately. The company said Richey has been with corporate predecessor (NSDQ:ZNGA) since 2001 through the merger last year with Sorin Group.
Read more
Schuler resigned from Hansen Medical board
Hansen Medical (NSDQ:HNSN) said board member Jack Schuler stepped down from its board of directors Jan. 12.
Read more
Skyline Medical taps PalliaTech CEO Taney for board
Skyline Medical said it named YY Taney, CEO of cannabinoid medicines developer PalliaTech, to its board of directors.
Read more
The post Bioventus taps ex-Medtronic CEO Hawkins for chairman | Personnel Moves appeared first on MassDevice.
from MassDevice http://ift.tt/1Ovwc50
Cap comentari:
Publica un comentari a l'entrada